1、novotech-AUGUST 12,2024Gastric Cancer-Global Clinical Trial Landscape(2024)GC is the 5th most diagnosed cancer and the 5th leading cause of cancer mortality,character-ized by uncon-trolled cell growth in the stomach wallThe content of this publication is proprietary to Novotech Health Holdings.No pa

2、rt of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Ple

3、ase note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken

4、by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?In the Asia-Pacific region,China reported a relatively higher incidence of GC casesThe United States reported the highest number of GC cases in North AmericaIn Europe,Germany recorde

5、d a relatively higher incidence of GCIn ROW,Brazil had the highest incidence of GCMarketed drugs emphasize antibody therapies targeting HER2(e.g.,trastuzum-ab)and immune checkpoint inhibitors like PD-1/PD-L1 inhibi-tors(e.g.,pembroli-zumab,nivolumab)Phase III trials are advancing immunotherapy optio

6、ns and antibody-drug conjugates(e.g.,trastuzumab emtan-sine),showing promis-ing advancement in GC treatmentGASTRIC CANCERTRIAL CONTRIBUTIONSThe U.S.and Asia-Pacific region show similar recruitment ratesGASTRIC CANCER(GC)GLOBAL CLINICAL TRIAL LANDSCAPE(2024)5%ROW55%NORTH AMERICA&EUROPE45%ASIA-PACIFIC